NPPB and atrial fibrillation: Taken together, device-anchored evidence indicates that NT-proBNP (and possibly troponin) may enrich for more sustained subclinical AF burden in ILR cohorts, whereas prediction of short-duration AHRE in pacemaker recipients is inconsistent and readily attenuated by structural confounding.